
    
      This is a multi-institutional, double-blinded, randomized study comparing docetaxel plus
      doxercalciferol versus docetaxel plus placebo in patients with metastatic hormone refractory
      prostate cancer. Docetaxel is given intravenously on days 1, 8 and 15 for every 28 day cycle
      and doxercalciferol or placebo is taken orally every day of the 28 day cycle. Please refer to
      the Eligibility Criteria below for key inclusion and exclusion criteria.
    
  